ArticleJournal for immunotherapy of cancer2022

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.

Xiaoyan Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.